TPD

FRESOR Leads the Vaping Industry with Innovative Product Series

Retrieved on: 
fredag, september 15, 2023
Taste, Safety, Pinnacle, Child, Cornerstone, TPD, Herbal cigarette, Video game

Its advanced leak-proof structure and exceptional energy efficiency redefine the vaping industry, allowing for more puffs while adhering to TPD regulations.

Key Points: 
  • Its advanced leak-proof structure and exceptional energy efficiency redefine the vaping industry, allowing for more puffs while adhering to TPD regulations.
  • FRESOR 2023 new product launch event stands as a resounding success, showcasing unwavering dedication to innovation and safety.
  • With the formidable FRESOR NOVA and its innovative product series, it is set to revolutionize your vaping experience.
  • FRESOR is about to launch a new product series with a larger capacity and is committed to continuous innovation to bring you the best e-cigarette technology.

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

Retrieved on: 
torsdag, september 7, 2023
Therapy, Cancer, TPD, Research, Antibody, Seagen, ET, Patient, Webcast, ADC, Bone marrow, DAC, Safety, Fine chemical, Vaccine

SAN FRANCISCO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc. to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer. The collaboration between the two companies will focus on an innovative approach to combine two powerful technologies to target cancer—antibody-drug conjugation (ADC) and targeted protein degradation (TPD)—with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.

Key Points: 
  • As part of the multi-year collaboration, Nurix will use its proprietary DELigase platform to develop a suite of targeted protein degraders against multiple targets nominated by Seagen that are suitable for antibody conjugation.
  • Given the potential to conjugate multiple antibodies to unique degraders, several DAC drugs may be developed and commercialized within this collaboration.
  • At 8:30 a.m., ET, September 7, 2023, Nurix will host a conference call and webcast to discuss this update.
  • A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.

FEELM and OS Vape Make a Joint Debut at Dortmund, Setting a New 800+ Puff Standard for Germany's Disposable Market

Retrieved on: 
torsdag, september 14, 2023
Tobacco, Retail, Specialty, Taste, Partnership, Exhibition, Culture, OS, TPD, Drinking, Heated tobacco product, System, Smoking, Industrial design

This distinguished gathering provides a platform for industry professionals to interact with top-tier representatives spanning retail, manufacturing, and service sectors.

Key Points: 
  • This distinguished gathering provides a platform for industry professionals to interact with top-tier representatives spanning retail, manufacturing, and service sectors.
  • OS, recognized as a dominant force in Germany's shisha product market, ventured into the disposable vape industry.
  • This represents an impressive 30%+ enhancement in puff count compared to other common disposable products, establishing a new standard under TPD compliance.
  • Given the debut of the 800+ puff disposable product in Germany, there was keen interest in the technical solution behind it.

Partners Life Launches Medical Claims on the FINEOS Platform

Retrieved on: 
tisdag, september 5, 2023
Professional Services, Technology, Insurance, Software, Human Resources, Partners Life, FINEOS, Case management (US healthcare system), LISA, TPD, Total permanent disability insurance, Trauma, Life insurance, Health insurance

Partners Life, one of New Zealand’s largest private life and health insurance companies, has become the first insurer to successfully launch medical claims on the FINEOS Platform, as outlined in a new case study .

Key Points: 
  • Partners Life, one of New Zealand’s largest private life and health insurance companies, has become the first insurer to successfully launch medical claims on the FINEOS Platform, as outlined in a new case study .
  • The move to the cloud-native purpose-built FINEOS Platform enables Partners Life to provide enhanced claims processing, reduced claims leakage, and streamlined user experience to 300,000 Kiwis.
  • Early last year, Partners Life became the first life insurance company in New Zealand to go live on the FINEOS Platform, replacing its legacy system with FINEOS Claims for life, total and permanent disability (TPD), trauma and income protection.
  • The second phase of the project, completed this year, brought the component-based capabilities of FINEOS AdminSuite to medical claims at Partners Life through the market-tested, preconfigured FINEOS Life Insurance Solution Australasia (LISA).

Plug Power Hosts Analyst Day, Showcasing the World’s First 15TPD Green Hydrogen Plant

Retrieved on: 
onsdag, augusti 23, 2023
Communication, Electrolysis, Marketing, Hydrogen, EVP, TPD, National Clean Energy Business Plan Competition, Plant, GM, Security (finance), Plug

LATHAM, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today will host its Analyst Day showcasing the accomplishments to date of its 15 ton per day (TPD) liquid green hydrogen plant in Camden County, Georgia.

Key Points: 
  • LATHAM, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today will host its Analyst Day showcasing the accomplishments to date of its 15 ton per day (TPD) liquid green hydrogen plant in Camden County, Georgia.
  • Plug will share how the Georgia plant strengthens Plug’s long-term position as the global leader in green hydrogen production and supplier of electrolyzers.
  • The plant is grid-connected, which should ensure a steady supply of power that is critical for a liquid hydrogen plant.
  • Plug is excited to showcase the plant that will help ensure demand as customers expedite adoption of green hydrogen and decarbonize multiple different industries.

Italy: Oral Tobacco, Nicotine Pouch and Heated Tobacco Regulation - ResearchAndMarkets.com

Retrieved on: 
måndag, augusti 21, 2023
Tobacco, Retail, Tobacco Products Directive, Policy, ADM, Knowledge, Heated tobacco product, TPD, Customs

The "Italy: Oral Tobacco, Nicotine Pouch and Heated Tobacco Regulation" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy: Oral Tobacco, Nicotine Pouch and Heated Tobacco Regulation" report has been added to ResearchAndMarkets.com's offering.
  • The Tobacco Products Directive (TPD)-implementing decree, Legislative Decree 6/2016, defines heated tobacco products as novel smokeless tobacco products, which are subject to more lenient regulation than cigarettes in terms of public place usage and taxation.
  • This report provides a detailed overview of Italy's regulatory framework for heated tobacco and herbal heated products, covering all policy areas from product and packaging requirements to taxation and sanctions
    A ban on all oral tobacco products except chewing tobacco is established in the Tobacco Products Directive (TPD)-implementing decree, Legislative Decree 6/2016.
  • Nicotine pouches do not fall under the TPD-implementing decree, and so are not considered either tobacco or tobacco-related products.

DejaVoo Unveils New Disposable Products in the UK Market

Retrieved on: 
fredag, augusti 18, 2023
Tobacco, Retail, TPD, Pink Lady, Multimedia, Sale, Engineering, Growth, Enigmatic, Herbal cigarette, Poultry farming

DejaVoo, a rising star in the field of disposable vape brands, unveils its latest offerings, Fresh Cube and Phantom in the UK market.

Key Points: 
  • DejaVoo, a rising star in the field of disposable vape brands, unveils its latest offerings, Fresh Cube and Phantom in the UK market.
  • View the full release here: https://www.businesswire.com/news/home/20230818922351/en/
    Fresh Cube and Phantom (Photo: Business Wire)
    As an indispensable market of the global vaping industry, the UK has witnessed fierce competition in the field of disposable.
  • While the majority of disposable products are backed by cotton coil, DejaVoo differentiates itself with the FEELM Max ceramic coil solution, delivering 800+ puffs and setting a new benchmark under TPD compliance.
  • Fresh Cube and Phantom exceed expectations by offering over 800 puffs, a remarkable 30%+ growth in puff count when measured against the most prevalent disposable products in the market.

New to The Street Announces its Six Corporate Guests TV Interviews; Broadcastings on Newsmax and The FOX Business Network, Airings Start on Saturday, August 12, 2023, at 3:30 PM ET

Retrieved on: 
fredag, augusti 11, 2023
Sustainability, Nanoparticle, Sport, Internet, Fox Business, Fertilizer, Vegetable, Privacy, Wood, Scientist, Vitamin, Soil, VRM, MLB, FMCG, FMCG in India, NFL, Interview, OTCQB, Cosmetics, Language, Final good, Athlete, Administration, NASCAR, Corporation, Host, Growth, Climate, CSE, Pressure, Street, IP, Nasdaq MarketSite, FRA, Clean Seas Seafood, Justin, Water, CBD, CFO, WWE, Television presenter, Partnership, Peer review, NHL, Nutrient, TPD, Moroccan, PROMO, OTC, OTCQX, CSM, Pyrolysis, Multi, AI, Red Cloud (rapper), Television, Management, Newsmax, Earth, Alain

New to The Street's Newsmax and the FOX Business Network episodes featuring the following Six (6) Corporate Guests:

Key Points: 
  • New to The Street's Newsmax and the FOX Business Network episodes featuring the following Six (6) Corporate Guests:
    1).
  • Game Time Productions recently announced a 3-year corporate partnership collaboration with the NFL team, New York Jets.
  • The interview will air on Newsmax on August 12, 2023, at 3:30 PM ET, and the FOX Business Network on August 14, 2023, at 10:30 PM PT.
  • The interview will air on Newsmax on August 12, 2023, at 3:30 PM ET, and the FOX Business Network on August 14, 2023, at 10:30 PM PT.

Brooge Renewable Energy Limited Successfully Concludes Feasibility Study for Green Ammonia Project, Ushering in a Bright and Sustainable Energy Future in UAE

Retrieved on: 
onsdag, augusti 2, 2023
Feasibility study, Interim, KTPA, Severn Tidal Power Feasibility Study, TPD, Energy, BROG, IRR, MTPA, Environment, Renewable energy

On August 11, 2022, the Company announced that it engaged EY to conduct the Feasibility Study for its Green Ammonia Project in Abu Dhabi, UAE.

Key Points: 
  • On August 11, 2022, the Company announced that it engaged EY to conduct the Feasibility Study for its Green Ammonia Project in Abu Dhabi, UAE.
  • Green ammonia has gained widespread recognition as an efficient and clean carrier of green hydrogen, poised to play a crucial role in meeting global decarbonization targets by 2050.
  • The Green Ammonia Project will establish a world-class export-focused green ammonia production facility with capacity of 1950 Tons Per Day (TPD).
  • "We are extremely pleased to announce the successful completion of the Feasibility Study for our Green Ammonia Project," said Lina Saheb, Interim CEO of Brooge Energy Limited.

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Retrieved on: 
tisdag, juli 11, 2023
DLBCL, Food and Drug Administration, Clinical trial, NHL, Pharmacokinetics, TPD, Research, Patient, Cancer, American Cancer Society, FDA, Food, Safety, Pharmaceutical industry, Salinicola salarius, IND

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces U.S. Food and Drug Administration (FDA) clearance of the company’s investigational new drug (IND) application to commence a Phase 1 clinical trial with SP-3164 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Salarius expects to begin treating patients in the dose-escalation portion of the trial in the second half of 2023 to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics.

Key Points: 
  • Salarius expects to begin treating patients in the dose-escalation portion of the trial in the second half of 2023 to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics.
  • RareDiseaseAdvisor estimates that DLBCL is the most common type of NHL, accounting for approximately 31% of NHL cases in Western countries2.
  • During the trial, Salarius will be assessing the applicability of the gene signature in predicting response to SP-3164.
  • Previous research with similar agents indicates that patients with an identifiable gene signature may be more likely to respond to SP-3164 treatment.